About Oncodesign
Oncodesign is a company based in Dijon (France) founded in 1995 was acquired by Edmond de Rothschild in October 2022.. Oncodesign has raised $4.71 million across 1 funding round from investors including Edmond de Rothschild, Banque de Vizille and Avenir Entreprises. Oncodesign offers products and services including OncoSNIPER, Nanocyclix, and PROMETHE. Oncodesign operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Dijon, France
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.71 M (USD)
in 1 rounds
-
Latest Funding Round
$4.71 M (USD), Series A
May 22, 2008
-
Investors
Edmond de Rothschild
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Edmond de Rothschild
(Oct 19, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oncodesign
Oncodesign offers a comprehensive portfolio of products and services, including OncoSNIPER, Nanocyclix, and PROMETHE. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Technology for targeting cancer resistance in precision medicine.
Platform developing novel compounds for oncology treatments.
Tool for advancing biopharmaceutical research and diagnostics.
Unlock access to complete
Leadership Team
4 people
Creative and Marketing Team
1 people
Data Analysis and Operations Team
1 people
Unlock access to complete
Funding Insights of Oncodesign
Oncodesign has successfully raised a total of $4.71M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.71 million completed in May 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $4.7M
-
First Round
First Round
(22 May 2008)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2008 | Amount | Series A - Oncodesign | Valuation | Banque de Vizille , Avenir Entreprises |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Oncodesign
Oncodesign has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Edmond de Rothschild, Banque de Vizille and Avenir Entreprises. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Content on business, technology, and digital trends is provided.
|
Founded Year | Domain | Location | |
|
Diversified asset management, corporate advisory, and private equity firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Oncodesign
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Oncodesign
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oncodesign Comparisons
Competitors of Oncodesign
Oncodesign operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oncodesign
Frequently Asked Questions about Oncodesign
When was Oncodesign founded?
Oncodesign was founded in 1995 and raised its 1st funding round 13 years after it was founded.
Where is Oncodesign located?
Oncodesign is headquartered in Dijon, France. It is registered at Dijon, Bourgogne-franche-comte, France.
Is Oncodesign a funded company?
Oncodesign is a funded company, having raised a total of $4.71M across 1 funding round to date. The company's 1st funding round was a Series A of $4.71M, raised on May 22, 2008.
What does Oncodesign do?
Oncodesign was founded in 1995 in Dijon, France, as an oncology-focused contract research organization. Preclinical evaluations of anti-cancer therapies are conducted using three main platforms: PREDICT for standard in vitro and in vivo pharmacology, Chi-Mice for humanized chimeric models in vivo, and PharmImage for non-invasive multimodal imaging. Additionally, Nanocyclix technology is applied in discovery processes to develop selective macrocyclic kinase inhibitors, supporting therapeutic assessments in the oncology sector.
Who are the top competitors of Oncodesign?
Oncodesign's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Oncodesign offer?
Oncodesign offers OncoSNIPER, Nanocyclix, and PROMETHE.
Who are Oncodesign's investors?
Oncodesign has 3 investors. Key investors include Edmond de Rothschild, Banque de Vizille, and Avenir Entreprises.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.